INDAPTUS THERAPEUTICS INC. - COMMON STOCK

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

08 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

22 نوفمبر 2024 08:36:14 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

11 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

07 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

23 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

22 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

15 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire